Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $67.54 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-07.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2023-03-07
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2020-03-31 was $4.32.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $67.54, a 44.00% decline from fiscal 2021.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $120.60, a 2158.43% increase from fiscal 2020.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2020 was $5.34, a 7.88% increase from fiscal 2019.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2019 was $4.95, a 24.37% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $67.54 10-K · filed 2023-03-07 | ||||
| 2021-12-31 | $120.60 10-K · filed 2023-03-07 | $4.02 10-K · filed 2022-03-08 | |||
| 2020-12-31 | $5.34 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $4.68 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $4.50 10-Q/A · filed 2020-08-31 | ||||
| 2020-03-31 | $4.32 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | $4.95 10-K · filed 2021-03-15 | ||||
| 2018-12-31 | $3.98 10-K · filed 2020-03-16 | ||||
| 2017-12-31 | $2.60 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |